OVERVIEW

The goals of this activity are to help participants examine synthesized data from completed studies, discuss the novel investigational agents available in ongoing clinical trials, and describe the rational for and results of studies that include novel agents targeting oncogenic relevant molecular alterations for the treatment of patients with advanced cancer. This knowledge will enable them to appropriately utilize new treatments available to cancer patients, provide support for current and future oncology clinical trials, and become stronger leaders in the area of oncology research. In sum, this program will convey information on how to better implement precision medicine in oncologic care, leading to better outcomes for patients suffering from cancer.

TARGET AUDIENCE

This activity is been designed for physicians and other healthcare professionals currently involved in the diagnosis, screening, and treatment of cancer patients.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

• State the clinical effects of novel experimental agents; including but not limited to immunotherapeutic approaches other than PD1 and CTLA4 checkpoint inhibitors, nuclear hormone receptor modulating agents, and epigenetic targeted drugs;
• Cite the relevant pharmacologic and biologic effects of novel anti-cancer agents through the use of blood and tissue samples as well as standard and novel imaging approaches including novel PET tracer imaging and circulating tumor DNA assays;
• Identify how to assess patient suitability for participation in ongoing and upcoming cancer clinical trials and projects;
• Discuss advances in the use of systemic therapies for cancer; including those targeting specific molecular alterations such as DNA repair mutations, specific chromosomal translocations, and tyrosine kinase mutations.

ACCREDITATION

Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For more information please visit the official event page.